ROCKET PHARMACEUTICALS INC (RCKT)

US77313F1066 - Common Stock

26.88  -0.37 (-1.36%)

Buy % Consensus

85

ChartMill assigns a Buy % Consensus number of 85% to RCKT. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 52.58. This target is 95.6% above the current price.
RCKT was analyzed by 20 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about RCKT.
In the previous month the buy percentage consensus was at a similar level.
RCKT was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 26.8839.3949.9852.5868.25 - 46.54% 85.94% 95.60% 153.91%
Up and Down Grades
Date Firm Action Rating
2024-03-01 UBS Maintains Buy -> Buy
2024-02-27 Cantor Fitzgerald Maintains Overweight -> Overweight
2024-02-27 JP Morgan Maintains Overweight -> Overweight
2024-02-13 Needham Reiterate Buy -> Buy
2024-01-31 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-11-07 Needham Reiterate Buy -> Buy
2023-10-24 Cantor Fitzgerald Initiate Overweight
2023-09-13 Needham Maintains Buy -> Buy
2023-09-13 Stifel Reiterate Buy -> Buy
2023-08-11 Chardan Capital Reiterate Buy -> Buy
2023-08-11 Canaccord Genuity Maintains Buy -> Buy
2023-08-10 Needham Reiterate Buy -> Buy
2023-08-10 Stifel Maintains Buy -> Buy
2023-05-23 Needham Reiterate Buy -> Buy
2023-05-08 Chardan Capital Maintains Buy
2023-05-05 Needham Reiterate Buy
2023-05-05 Raymond James Maintains Outperform
2023-04-19 Needham Reiterate Buy
2023-03-01 Chardan Capital Reiterate Buy
2023-02-28 Needham Reiterate Buy
2023-02-01 Morgan Stanley Initiate Overweight
2023-01-23 SVB Leerink Maintains Outperform
2022-12-23 B of A Securities Maintains Buy
2022-12-22 SVB Leerink Maintains Outperform
2022-12-06 SVB Leerink Maintains Outperform
2022-11-08 Canaccord Genuity Initiate Buy
2022-11-07 Raymond James Maintains Outperform
2022-11-04 Needham Maintains Buy
2022-11-01 BTIG Initiate Buy
2022-10-03 Chardan Capital Maintains Buy